Vicarious Surgical has appointed Sarah Romano as its new chief financial officer (CFO). Romano will take office on April 1, 2025.

She will oversee the company’s financial strategy. Romano has a record of driving growth and value creation in public companies—especially in the healthcare sector—through successful fundraising and M&A initiatives.

This appointment follows the departure of previous CFO William Kelly, who left the company to pursue other career opportunities after a four-year tenure.

Romano was most recently CFO of Entero Therapeutics, where she oversaw financial strategy, operations, and compliance. There, she raised significant funding and executed product in-licensing partnerships. She was also previously CFO of Kiora Pharmaceuticals, where she secured more than $50 million in funding and led M&A activities.

Earlier in her career, Romano moved through positions of growing responsibility. This includes corporate controller, with responsibilities covering budget reviews, financial forecasting and analysis, internal controls oversight, and SEC reporting.

“We are delighted to welcome Sarah to the Vicarious Surgical team,” said Vicarious Surgical c-founder and CEO Adam Sachs. “Her exceptional financial strategy acumen makes her an invaluable asset to our company and the ideal partner to lead our finance organization. I’m confident her expertise and strategic vision will be instrumental in driving our financial objectives and overall success.”

“The energy and momentum at Vicarious Surgical is palpable as we approach our first clinical use cases later this year,” added Romano. “I’m thrilled to bring my experience to the team and play a key role in ensuring we have the financial strength to achieve our milestones and beyond.”

Last month, Vicarious chief operating officer John Mazzola revealed he would retire, effective April 1 of this year.